372118-00-8
C6H6N2O4
170.12
1.58±0.1
Purity 99.0% min (HPLC)
Off-white solid
Psoriasis
Deucravacitinib
tyrosine kinase 2
N
2022
GMP-like
Availability: | |
---|---|
Supply Chain
Based on the proriasis market analysis, the 2023 demand for this intermediate methyl 4-hydroxy-6-oxo-1H-pyridazine-3-carboxylate (CAS No. 372118-00-8) was esimated to be 4.42 Kg, depending on the specific route. Considering the deeper market penetration and the completion of Deucravacitinib clinical trials on other diseases, the demand is to grow.
As of July 29, 2024, there are 51 potential suppliers manufacturing Deucravacitinib intermediate methyl 4-hydroxy-6-oxo-1H-pyridazine-3-carboxylate (CAS No. 372118-00-8), including 40 factories and 11 labs, among which:
- The 25th percentile has an average registered capital of 1 million CNY;
- The 50th percentile has an average registerd capital of 2 million CNY;
- The 75th percentile has an average registered capital of 11.25 million CNY.
Feeling overwhelmed? Contact Unibest if you need us to quality-check other sources to strengthen your supply chain or to find a tailored solution for your specific procurement request.
Usage and ROS Analysis
Deucravacitinib, CAS No. 1609392-27-9, is a deuterated compound, and structurally speaking, four scaffolds can be identified:
- a benzene - triazole scaffold (scaffold A)
- a deuterated pyridazine (scaffold B + scaffold C)
- a three membered ring (scaffold D)
This compound, methyl 4-hydroxy-6-oxo-1H-pyridazine-3-carboxylate, CAS No. 372118-00-8, is an alternative pyridazine scaffold (scaffold B) of Deucravacitinib as shown below. It is a methyl ester, in contrast to the original intermediate CAS No. 1352925-63-3 where it is the ethyl group on the ester bond.
The ester bond is to break, the methyl group is to be replaced by the amine group of the deuterium source, CAS No 7436-22-8 to form the deuterated scaffold of Deucravacitinib API. This is an early stage of Deucravacitinib intermediate in the synthesis route.
Zhuang, L. et al. Tyrosine Kinase 2 Inhibitors, Preparation Methods and Medicinal Uses Thereof. (2022).
Liu, J. et al. Tyrosine Kinase 2 (tyk2) Degradation Compounds and Methods of Use. (2022).
Greenwood, J. R. et al. Tyk2 Inhibitors and Uses Thereof. (2018).
Šagud, I. et al. Solid State Forms of Deucravacitinib, Deucravacitinib Hcl and Process for Preparation of Deucravacitinib and Intermediates. (2023).
Chen, K. et al. Process for the Preparation of 6-(cyclopropaneamido)-4-((2-Methoxy-3-(1-Methyl-1h-1,2,4-Triazol-3-Yl)phenyl)amino)-N-(methyl-D3)pyridazine-3-Carboxamide. (2018).
Li, P., Wang, P., Zhou, P., Zhao, X. & Wei, Q. Method for Synthesizing Deucravacitinib. (2024).
Wang, W. et al. Hydroxamate Compound, Preparation Method Therefor and Application Thereof. (2022).
Wrobleski, S. T. et al. Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165. J. Med. Chem. 62, 8973–8995 (2019).
Chen, X. & Pang, Y. Heterocyclic Compounds for Inhibiting Tyk2 Activities. (2021).
Du, J. & Guo, L. Crystal Form of Pyridazine Derivative Free Base, and Preparation Method Therefor and Use Thereof. (2022).
Li, H., Li, Z., Zhou, J., Xu, J. & Zhang, Q.-Y. Compounds and Methods for Inhibiting Viral Replication and Methods of Treating and Preventing Flaviviral Infections. (2022).
Moslin, R. M., Weinstein, D. S., Wrobleski, S. T., Tokarski, J. S. & Kumar, A. AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHα RESPONSES. (2014).
Brimert, T., Johnsson, R., Leffler, H., Nilsson, U. & Zetterberg, F. Alpha-D-Galactoside Inhibitors of Galectins. (2016).